image_pdfimage_print

Tezos ICO has issues, is this a warning of things to come?

Tezos $XTZ recent ICO, backed by US billionaire fund manager Tim Draper looks to be coming off the rails, and is perhaps a warning of the quality and quantity of ICO’s coming to the crypto currency market.

Once easy money being made, in any market, it attracts a whole set of new people looking to take advantage, and self enrich at the expense of others.  Continue reading

Barkerville sues former CEO Frank Callaghan over confidential data

Barkerville Gold {TSX.V: BGM} are, according to veteran Vancouver based reporter Mike Caswell,  suing former CEO Frank Callaghan over the return of confidential data acquired from the company.

The dispute centers on a piece of ground BGM has an interest in that has now been staked and transferred to Standard Drilling, a company owned by Frank Callaghan. Continue reading

Inovio Commences Phase 1b/2 bladder cancer trial

PLYMOUTH MEETING, Pa.Oct. 16, 2017 – Inovio Pharmaceuticals {NASDAQ: INO} announced initiation of a phase 1b/2 immuno-oncology trial to evaluate Genentech/Roche’s atezolizumab (TECENTRIQ®) in combination with Inovio’s INO-5401, a T cell activating immunotherapy encoding multiple antigens, and INO-9012, an immune activator encoding IL-12. Continue reading

Barkerville Gold intersects high grade gold at the Shaft Zone.

Barkerville Gold Mines Ltd. {TSX.V: BGMannounced additional drilling results from the ongoing 130,000 metre Phase II Island Mountain exploration and infill drilling program at the Company’s flagship Cariboo Gold Project.

The Company is currently exploring and delineating the Valley and Shaft Zones with nine drill rigs, while a tenth drill is expanding the known mineralization on the BC Vein. Continue reading

Inovio’s Positive Zika Vaccine Study Data Published in New England Journal of Medicine

Inovio Pharmaceuticals, Inc. {NASDAQ:INO} reported today on positive safety and immune response results from a first-in-man, multi-center phase 1 trial of a vaccine against the Zika virus.

The phase 1 trial of Inovio’s DNA-based Zika vaccine (GLS-5700) induced high levels of binding antibodies in 100% of participants. Continue reading